Richard T Maziarz1,1, Annie Guérin2,2, Geneviève Gauthier2,2, Julie Heroux2,2, Maryia Zhdanava2,2, Eric Q Wu3,3, Simu K Thomas4,4, Lei Chen4,4. 1. Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239-3098, USA. 2. Analysis Group Inc., 1000 De La Gauchetière Ouest, Bureau 1200, Montréal, QC H3B 4W5, Canada. 3. Analysis Group Inc., 14th floor, 111 Huntington Ave, Boston, MA 02199-7668, USA. 4. Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA.
Abstract
AIM: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases. PATIENTS & METHODS: Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT. RESULTS: HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years. CONCLUSION: HRU and direct costs associated with allogeneic HSCTs are substantial.
AIM: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases. PATIENTS & METHODS: Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT. RESULTS: HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years. CONCLUSION: HRU and direct costs associated with allogeneic HSCTs are substantial.
Authors: Denise M Oliansky; J Douglas Rizzo; Peter D Aplan; Robert J Arceci; Louis Leone; Yaddanapudi Ravindranath; Jean E Sanders; Franklin O Smith; Fiona Wilmot; Philip L McCarthy; Theresa Hahn Journal: Biol Blood Marrow Transplant Date: 2007-01 Impact factor: 5.742
Authors: Akiko M Saito; Corey Cutler; David Zahrieh; Robert J Soiffer; Vincent T Ho; Edwin P Alyea; John Koreth; Joseph H Antin; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2008-02 Impact factor: 5.742
Authors: C Fred LeMaistre; Stephanie Farnia; Stephen Crawford; Joseph McGuirk; Richard T Maziarz; James Coates; Dennis Irwin; Patricia Martin; James L Gajewski Journal: Biol Blood Marrow Transplant Date: 2013-03-21 Impact factor: 5.742
Authors: John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: J M Talano; M A Pulsipher; H J Symons; O Militano; E B Shereck; R H Giller; L Hancock; E Morris; M S Cairo Journal: Bone Marrow Transplant Date: 2014-05-12 Impact factor: 5.483
Authors: Andrine R Swensen; Howard G Birnbaum; Kristina Secnik; Maryna Marynchenko; Paul Greenberg; Ami Claxton Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-12 Impact factor: 8.829
Authors: Xiao Jun Wang; Yi-Ho Wang; Matthew Jian Chun Ong; Christina Gkitzia; Shui Yen Soh; William Ying Khee Hwang Journal: Clinicoecon Outcomes Res Date: 2022-05-03
Authors: Samantha Aliza Hershenfeld; John Matelski; Vicki Ling; Michael Paterson; Matthew Cheung; Peter Cram Journal: BMJ Open Date: 2020-10-31 Impact factor: 2.692